Abstract:Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder. Its molecular mechanism is still unclear, and pharmacological treatments are unsatisfactory. Transient receptor potential vanilloid 4 (TRPV4) is a nonselective Ca2+ channel. It has recently emerged as a critical risk factor in the pathophysiology of neuronal injuries and cerebral diseases. Our previous study reported that TRPV4 contributed to endoplasmic reticulum (ER) stress in the MPP+-induced cell model of PD. In the present study, we detected the role and the mechanism of TRPV4 in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice. Methods: Intracerebral injection of an adeno-associated virus (AAV) into the substantia nigra (SN) of mice was used to knockdown or upregulate the expression of TRPV4 and intraperitoneal injection of MPTP. Rotarod and pole tests were used to evaluate the locomotor ability of mice. We used immunohistochemistry, Nissl staining and Western blot to detect the alterations in the number of tyrosine hydroxylase (TH)-positive neurons, Nissl-positive neurons, the levels of ER stress-associated molecules and proinflammatory cytokines in the SN. Results: The SN was transfected with AAV for 3 weeks and expressed the target protein with green fluorescence. Knockdown of TRPV4 via injection of a constructed AAV-TRPV4 shRNAi into the SN alleviated the movement deficits of PD mice. Upregulation of TRPV4 via injection of a constructed AAV-TRPV4 aggravated the above movement disorders. The expression of TRPV4 was upregulated in the SN of MPTP-treated mice. Injection of AAV-TRPV4 shRNAi into the SN rescued the number of TH-positive and Nissl-positive neurons in the SN decreased by MPTP, while injection of AAV-TRPV4 induced the opposite effect. Moreover, MPTP-decreased Sarco/endoplasmic reticulum Ca2+-ATPase 2 (SERCA2) and pro-cysteinyl aspartate specific proteinase-12 (procaspase-12), MPTP-increased Glucose-regulated protein 78 (GRP78), Glucose-regulated protein 94 (GRP94) and C/EBP homologous protein (CHOP) were inhibited by AAV-TRPV4 shRNAi infection, and enhanced by AAV-TRPV4. In the same way, MPTP-decreased procaspase-1, MPTP-increased Interleukin-18 (IL-18), Cyclooxgenase-2 (COX-2) and 5-Lipoxygenase (5-LOX) were inhibited by AAV-TRPV4 shRNAi, or further exacerbated by AAV-TRPV4. Conclusions: These results suggest that TRPV4 mediates ER stress and inflammation pathways, contributing to the loss of dopamine (DA) neurons in the SN and movement deficits in PD mice. Moreover, this study provides a new perspective on molecular targets and gene therapies for the treatment of PD in the future.

Deletion of the Transient Receptor Potential Melastatin 2 Gene Mitigates the 6-Hydroxydopamine-Induced Parkinson's Disease–Like Pathology

Inhibition of TRPM2 by AG490 Is Neuroprotective in a Parkinson’s Disease Animal Model

MPTP-Induced Impairment of Cardiovascular Function

Transient Receptor Potential Melastatin 2 Contributes to Neuroinflammation and Negatively Regulates Cognitive Outcomes in a Pilocarpine-Induced Mouse Model of Epilepsy.

The transient receptor potential melastatin 2: a new therapeutical target for Parkinson's disease?

Neuroprotective effects of TRPV1 by targeting GDF11 in the Mpp+/MPTP-induced Parkinson's disease model

TRPM2 As a Conserved Gatekeeper Determines the Vulnerability of DA Neurons by Mediating ROS Sensing and Calcium Dyshomeostasis.

Amelioration of Parkinson's disease by pharmacological inhibition and knockdown of redox sensitive TRPC5 channels: Focus on mitochondrial health

Neuroprotective Potential of HC070, a Potent TRPC5 Channel Inhibitor in Parkinson's Disease Models: A Behavioral and Mechanistic Study

Tet1-mediated activation of the Ampk signaling by Trpv1 DNA hydroxymethylation exerts neuroprotective effects in a rat model of Parkinson's disease

TRPV4 contributes to ER stress and inflammation: implications for Parkinson's disease

Tetramethylpyrazine Alleviated Cytokine Synthesis and Dopamine Deficit and Improved Motor Dysfunction in the Mice Model of Parkinson’s Disease

Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson’s Disease

TLR2 Deficiency is Beneficial at the Late Phase in MPTP-induced Parkinson' Disease Mice.

Neuroprotective Effects of Stemazole in the Mptp-Induced Acute Model of Parkinson'S Disease: Involvement of the Dopamine System

Repetitive Transcranial Magnetic Stimulation Alleviates MPTP-Induced Parkinson’s Disease Symptoms by Regulating CaMKII-CREB-BMAL1 Pathway in Mice Model

Repetitive Transcranial Magnetic Stimulation Alleviates MPTP-Induced Parkinson's Disease Symptoms by Regulating CaMKII-CREB-BMAL1 Pathway in Mice Model

Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson's disease

Neuroprotective Effects of Pramipexole Transdermal Patch in the MPTP-induced Mouse Model of Parkinson's Disease

Pharmacological inhibition of STING signaling attenuates MPTP-induced neuroinflammation and neurodegeneration in mouse parkinsonian models

Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.